Endoscopic transsphenoidal surgery has the best remission rates and fewest postoperative complications for adults with acromegaly, according to findings from a systematic review. In an article ...

Please provide your email address to receive an email when new articles are posted on . “Our colleagues in endocrinology should consider the presence or history of carpal tunnel syndrome when ...

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) for ...

A 23-year-old man was admitted to the hospital with severe dyspnoea, elevated body temperature, and rhinorrhoea. Several endocrinological disorders were known in the patient’s family. Echocardiography ...

SAN FRANCISCO—People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general ...

PITTSBURGH, Oct. 13, 2025 /PRNewswire/ -- PANTHERx® Rare has been chosen by Chiesi as the exclusive specialty pharmacy to distribute MYCAPSSA® (octreotide). The partnership aims to improve patient ...

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...